Staphylococcal Infections

4
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
267%
Peptide
133%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

AM-Pharma
AM-PharmaNetherlands - Utrecht
1 program
1
human lactoferrin peptide 1-11Phase 1/2Peptide1 trial
Active Trials
NCT00509847WithdrawnEst. Oct 2009
United Therapeutics
United TherapeuticsMD - Silver Spring
2 programs
2
NDV-3 investigational vaccinePhase 1Vaccine1 trial
NDV-3 vaccine with alum IMPhase 1Vaccine1 trial
Active Trials
NCT01273922Completed40Est. Dec 2011
NCT01447407Completed164Est. Dec 2012
M&
Merck & Co.RAHWAY, NJ
1 program
1
V710Phase 11 trial
Active Trials
NCT01324440Completed64Est. Oct 2007
Pfizer
PfizerNEW YORK, NY
1 program
linezolidN/A1 trial
Active Trials
NCT00666276Completed1,004Est. Apr 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AM-Pharmahuman lactoferrin peptide 1-11
United TherapeuticsNDV-3 vaccine with alum IM
United TherapeuticsNDV-3 investigational vaccine
Merck & Co.V710
Pfizerlinezolid

Clinical Trials (5)

Total enrollment: 1,272 patients across 5 trials

NCT00509847AM-Pharmahuman lactoferrin peptide 1-11

A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis

Start: Feb 2009Est. completion: Oct 2009
Phase 1/2Withdrawn
NCT01447407United TherapeuticsNDV-3 vaccine with alum IM

Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Start: Sep 2011Est. completion: Dec 2012164 patients
Phase 1Completed
NCT01273922United TherapeuticsNDV-3 investigational vaccine

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

Start: Jan 2011Est. completion: Dec 201140 patients
Phase 1Completed

Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)

Start: Sep 2006Est. completion: Oct 200764 patients
Phase 1Completed

Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)

Start: Feb 2007Est. completion: Apr 20111,004 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space